Abstract
This study presents an innovative methodology for predicting chemotherapy responses in colorectal cancer patients by integrating gene expression data from matched colorectal tumor and organoid samples. Employing Consensus Weighted Gene Co-expression Network Analysis (WGCNA) across multiple datasets, we identified key gene modules and hub genes linked to patient response to chemotherapy, focusing on 5-fluorouracil (5-FU). This integrative approach marks a significant advancement in precision medicine, enhancing the specificity and accuracy of chemotherapy regimen selection based on individual tumor profiles. Our predictive model, validated by independent datasets demonstrated improved accuracy over traditional methods. This strategy shows promise in overcoming typical challenges in high-dimensional genomic data analysis for cancer biomarker research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by US National Cancer Institute grant R37CA248289 (J.J.S), and Sylvester Comprehensive Cancer Center Intramural program SCCC-NIH-2022-11 (X.S.C).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All datasets used in the study are publicly available data from Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) and NCI Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All datasets used in the study are publicly available data from Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) and NCI Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/)
